Andrew K. Balo, EVP, Reg. Strategy, Clinical at DEXCOM INC (DXCM), sold 5,000 shares at $99.12 ($498K) on 2018-07-16, disclosed to the SEC on 2018-07-18.
Seasonal sale ($498k) by EVP, Reg. Strategy, Clinical — this insider has traded DXCM in July in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $99.12 | 2,700 | $268K | 53.8% |
| 2 | $99.90 | 1,800 | $180K | 36.1% |
| 3 | $100.73 | 500 | $50K | 10.1% |
| Total | $99.56 avg | 5,000 | $498K | 100% |
| Filing → |
| DXCM | SELL | 2021-07-08 | $2.4M | — | Filing → |
| DXCM | SELL | 2021-06-07 | $897K | — | Filing → |
| DXCM | SELL | 2021-03-12 | $4.0M | — | Filing → |